Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Alnylam Pharmaceuticals I...

    NASDAQ: ALNY · Real-Time Price · USD
    290.77
    1.77 (0.61%)
    At close: May 23, 2025, 3:59 PM
    291.42
    0.22%
    After-hours: May 23, 2025, 05:13 PM EDT
    0.61%
    Bid 280
    Market Cap 37.91B
    Revenue (ttm) 2.35B
    Net Income (ttm) -269.7M
    EPS (ttm) -2.11
    PE Ratio (ttm) -137.81
    Forward PE 154.62
    Analyst Buy
    Ask 296
    Volume 624,787
    Avg. Volume (20D) 995,433
    Open 286.38
    Previous Close 289.00
    Day's Range 284.25 - 291.12
    52-Week Range 146.79 - 304.39
    Beta 0.17

    About ALNY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ALNY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ALNY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 months ago
    +2.6%
    Alnylam Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
    2 months ago
    +11.75%
    Alnylam Pharmaceuticals shares are trading higher after the company secured FDA approval pf sNDA for its RNAi therapeutic, AMVUTTRA ,for treatment of ATTR-CM in adults.
    news image

    1 week ago · businesswire.com

    AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of ...

    news image

    1 week ago · businesswire.com

    Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship ...

    news image

    2 weeks ago · businesswire.com

    Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Secu...

    news image

    3 weeks ago · zacks.com

    Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

    ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

    news image

    3 weeks ago · seekingalpha.com

    Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstre...

    news image

    3 weeks ago · zacks.com

    Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

    While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t...

    news image

    3 weeks ago · zacks.com

    Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

    Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago.

    news image

    3 weeks ago · zacks.com

    Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

    Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo...

    news image

    3 weeks ago · businesswire.com

    Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for...

    news image

    1 month ago · zacks.com

    Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline

    Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Add to Watchlist